New Hope on the Horizon: Ketamine-Based Treatment for Parkinson’s

PharmaTher is moving closer to a potential breakthrough in Parkinson’s care with its ketamine-based treatment, branded as Ketarx, as the U.S. Food and Drug Administration (FDA) sets an approval decision date of August 9, 2025. 🎯 What Could This Mean for People with Parkinson’s? Ketamine is being studied for its ability to ease motor symptoms of Parkinson’s disease—especially tremors and dyskinesia (involuntary movements often caused by long-term use of levodopa). In clinical trials so far, low doses of ketamine have been shown to reduce dyskinesia in people with Parkinson’s, and the treatment was well tolerated. Importantly, these doses are not expected to cause sedation or anesthesia. 🧬 Why Ketamine? Parkinson’s disease results from the gradual loss of brain cells that produce dopamine, a key chemical for movement. Levodopa, a common treatment, helps replenish dopamine, but over time can lead to dyskinesia. Ketamine may help by calming overactive brain pathways, offering a new tool for managing these difficult side effects. 🧩 What’s Next? PharmaTher has: 📝 Submitted applications for use in Parkinson’s and other brain conditions 💡 Developed new delivery systems like a wearable pump and microneedle patches 🏭 Built U.S.-based manufacturing to avoid supply issues 🌍 Planned global approval efforts in Europe, the UK, Canada, Japan, and Asia-Pacific With funding secured through the approval date, the company is focused on getting ready to launch Ketarx in the U.S. and beyond—pending FDA approval. 🌍 A New Chapter for Parkinson’s Research? As more attention is given to innovative treatments like ketamine, researchers and companies are pushing forward with science-driven, patient-centered approaches to improve quality of life for people living with Parkinson’s.